Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023 Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May 11, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial… Continue reading Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
